Top-Rated StocksTop-RatedNASDAQ:DXCM DexCom (DXCM) Stock Forecast, Price & News $92.54 +3.92 (+4.42%) (As of 03:10 PM ET) Add Compare Share Share Today's Range$89.56▼$92.6250-Day Range$86.06▼$137.9352-Week Range$80.36▼$139.55Volume4.26 million shsAverage Volume2.90 million shsMarket Capitalization$35.89 billionP/E Ratio107.60Dividend YieldN/APrice Target$136.31 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability DexCom MarketRank™ ForecastAnalyst RatingModerate Buy2.93 Rating ScoreUpside/Downside51.1% Upside$136.31 Price TargetShort InterestHealthy4.13% of Shares Sold ShortDividend StrengthN/ASustainability-0.76Upright™ Environmental ScoreNews Sentiment1.06Based on 15 Articles This WeekInsider TradingSelling Shares$1.28 M Sold Last QuarterProj. Earnings Growth29.27%From $1.23 to $1.59 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.48 out of 5 starsMedical Sector10th out of 963 stocksSurgical & Medical Instruments Industry2nd out of 97 stocks 4.5 Analyst's Opinion Consensus RatingDexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $136.31, DexCom has a forecasted upside of 51.1% from its current price of $90.19.Amount of Analyst CoverageDexCom has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.13% of the outstanding shares of DexCom have been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in DexCom has recently decreased by 5.26%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDexCom does not currently pay a dividend.Dividend GrowthDexCom does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDexCom has received a 75.05% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Continuous glucose monitoring systems" and "Blood glucose monitors" products. See details.Environmental SustainabilityThe Environmental Impact score for DexCom is -0.76. Previous Next 3.9 News and Social Media Coverage News SentimentDexCom has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for DexCom this week, compared to 8 articles on an average week.Search Interest30 people have searched for DXCM on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows13 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is an increase of 18% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,275,573.00 in company stock.Percentage Held by InsidersOnly 0.41% of the stock of DexCom is held by insiders.Percentage Held by Institutions93.88% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for DexCom are expected to grow by 29.27% in the coming year, from $1.23 to $1.59 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DexCom is 104.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.52.Price to Earnings Ratio vs. SectorThe P/E ratio of DexCom is 104.87, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 116.07.Price to Earnings Growth RatioDexCom has a PEG Ratio of 1.63. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDexCom has a P/B Ratio of 16.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About DexCom (NASDAQ:DXCM) StockDexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Read More DXCM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DXCM Stock News HeadlinesSeptember 5, 2023 | marketbeat.comWhy Analysts Say GE's Healthcare Spinoff Has $20 Upside (DXCM)General Electric’s spinoff, GE HealthCare Technologies Inc., is delivering some impressive results and has growth opportunities well worth tuning in to.September 27, 2023 | finance.yahoo.comDexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On CapitalSeptember 27, 2023 | Micro-Cap Stock Trader (Ad)Windfall profits possible with this under-the-radar lithium stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 25, 2023 | americanbankingnews.comDexCom, Inc. (NASDAQ:DXCM) Director Steven Robert Pacelli Sells 411 SharesSeptember 22, 2023 | benzinga.comDexCom Unusual Options Activity For September 22September 21, 2023 | marketwatch.comDexCom Inc. stock falls Thursday, underperforms marketSeptember 21, 2023 | finance.yahoo.comDexcom Canada and RxFood Corporation Partner on Industry-Leading, AI-powered Nutrition and Glucose Monitoring Solution for Diabetes Management and Personalized Therapeutic NutritionSeptember 21, 2023 | finance.yahoo.comWeight-Loss Drugs Like Wegovy Are Bad News for These StocksSeptember 27, 2023 | Micro-Cap Stock Trader (Ad)Windfall profits possible with this under-the-radar lithium stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 21, 2023 | americanbankingnews.comDexCom, Inc. (NASDAQ:DXCM) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 20, 2023 | benzinga.comMassive Insider Trade At DexComSeptember 20, 2023 | finance.yahoo.com3 Healthcare Stocks That Turned $100,000 Into $1 Million in 10 YearsSeptember 19, 2023 | finance.yahoo.comDexcom U Kicks off 2023 Season With Expanded Roster of Athletes With Diabetes, Building on First-of-its-Kind NIL ProgramSeptember 18, 2023 | forbes.comWill DexCom Stock Recover To Its Pre-Inflation Shock Highs Of $160?September 17, 2023 | americanbankingnews.comDexCom (NASDAQ:DXCM) Price Target Cut to $131.00 by Analysts at Raymond JamesSeptember 15, 2023 | fool.comWhy DexCom Stock Dove by 5% TodaySeptember 12, 2023 | finance.yahoo.comDexCom (DXCM) Rises 7% in One Week: What's Driving It?September 12, 2023 | msn.comWhy DexCom May Be Up To 40% UndervaluedSeptember 12, 2023 | finance.yahoo.comDexcom Unlocks Access to Real-Time CGM for a Further Half a Million People With Diabetes in FranceSeptember 11, 2023 | benzinga.com$100 Invested In This Stock 15 Years Ago Would Be Worth $6,500 TodaySeptember 11, 2023 | finance.yahoo.comIs DexCom, Inc. (NASDAQ:DXCM) A High Quality Stock To Own?September 8, 2023 | forbes.comWith 2x Potential Returns Is DexCom A Better Pick Over Intuitive Surgical?September 7, 2023 | markets.businessinsider.comExpert Ratings for DexComSeptember 7, 2023 | msn.comDexcom Denies Weight Loss Drug Threat To CGM Sales - I'd Be A Little ConcernedSeptember 7, 2023 | marketwatch.comDexCom Inc. stock underperforms Thursday when compared to competitorsSeptember 7, 2023 | finance.yahoo.comStrength Seen in DexCom (DXCM): Can Its 6.5% Jump Turn into More Strength?September 6, 2023 | nasdaq.comUBS Maintains Dexcom (DXCM) Buy RecommendationSee More Headlines Receive DXCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter. Email Address DXCM Company Calendar Last Earnings7/27/2023Today9/27/2023Next Earnings (Estimated)10/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:DXCM CUSIP25213110 CIK1093557 Webwww.dexcom.com Phone(858) 200-0200Fax858-200-0201Employees7,600Year Founded1999Price Target and Rating Average Stock Price Forecast$136.31 High Stock Price Forecast$160.00 Low Stock Price Forecast$114.00 Forecasted Upside/Downside+50.9%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)$0.86 Trailing P/E Ratio105.02 Forward P/E Ratio73.43 P/E Growth1.63Net Income$341.20 million Net Margins11.18% Pretax Margin15.74% Return on Equity22.01% Return on Assets8.06% Debt Debt-to-Equity Ratio1.16 Current Ratio2.42 Quick Ratio2.21 Sales & Book Value Annual Sales$2.91 billion Price / Sales12.04 Cash Flow$1.37 per share Price / Cash Flow65.71 Book Value$5.52 per share Price / Book16.36Miscellaneous Outstanding Shares387,870,000Free Float386,282,000Market Cap$35.03 billion OptionableOptionable Beta1.12 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Kevin Ronald Sayer (Age 65)Exec. Chairman, CEO & Pres Comp: $2.22MMr. Jereme M. Sylvain (Age 43)Exec. VP, CFO & Chief Accounting Officer Comp: $841.14kMr. Jacob Steven Leach (Age 45)Exec. VP & COO Comp: $994.13kMr. Girish Naganathan (Age 46)Exec. VP & CTO Comp: $423.92kMr. Michael Jon Brown (Age 53)Exec. VP & Chief Legal Officer Comp: $954.46kMr. Shelly Ramasamy Selvaraj (Age 64)Sr. VP & Chief Information Officer Mr. Sean ChristensenDirector of Corp. Affairs & Head of Investor RelationsMr. Matthew Dolan (Age 42)Exec. VP of Strategy, Corp. Devel. & Dexcom Labs Ms. Sadie M. Stern (Age 48)Exec. VP & Chief HR Officer Mr. Steven R. Pacelli (Age 51)Exec. VP & MD of Dexcom Ventures More ExecutivesKey CompetitorsBaxter InternationalNYSE:BAXInsuletNASDAQ:PODDTeleflexNYSE:TFXBoston ScientificNYSE:BSXBecton, Dickinson and CompanyNYSE:BDXView All CompetitorsInsiders & InstitutionsBROOKFIELD Corp ON Bought 41,897 shares on 9/26/2023Ownership: 0.039%Steven Robert PacelliSold 411 sharesTotal: $36,332.40 ($88.40/share)Steven R AltmanSold 1,000 sharesTotal: $101,500.00 ($101.50/share)Bridgette P HellerSold 600 sharesTotal: $63,936.00 ($106.56/share)Prosperity Financial Group Inc.Bought 145 shares on 9/12/2023Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions DXCM Stock - Frequently Asked Questions Should I buy or sell DexCom stock right now? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DXCM shares. View DXCM analyst ratings or view top-rated stocks. What is DexCom's stock price forecast for 2023? 14 analysts have issued 1-year price targets for DexCom's stock. Their DXCM share price forecasts range from $114.00 to $160.00. On average, they anticipate the company's stock price to reach $136.31 in the next twelve months. This suggests a possible upside of 50.9% from the stock's current price. View analysts price targets for DXCM or view top-rated stocks among Wall Street analysts. How have DXCM shares performed in 2023? DexCom's stock was trading at $113.24 at the beginning of the year. Since then, DXCM stock has decreased by 20.2% and is now trading at $90.32. View the best growth stocks for 2023 here. Are investors shorting DexCom? DexCom saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 16,030,000 shares, a decrease of 5.3% from the August 31st total of 16,920,000 shares. Based on an average daily volume of 3,630,000 shares, the short-interest ratio is currently 4.4 days. View DexCom's Short Interest. When is DexCom's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023. View our DXCM earnings forecast. How were DexCom's earnings last quarter? DexCom, Inc. (NASDAQ:DXCM) posted its earnings results on Thursday, July, 27th. The medical device company reported $0.34 EPS for the quarter, topping analysts' consensus estimates of $0.22 by $0.12. The medical device company earned $871.30 million during the quarter, compared to analyst estimates of $841.16 million. DexCom had a net margin of 11.18% and a trailing twelve-month return on equity of 22.01%. The business's revenue for the quarter was up 25.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.17 EPS. Read the conference call transcript. What ETFs hold DexCom's stock? ETFs with the largest weight of DexCom (NASDAQ:DXCM) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Subversive Mental Health ETF (SANE), Global X Internet of Things Thematic ETF (SNSR), American Century Mid Cap Growth Impact (MID), Fidelity Digital Health ETF (FDHT), iShares U.S. Medical Devices ETF (IHI), Global X Telemedicine & Digital Health ETF (EDOC) and Neuberger Berman Disrupters ETF (NBDS). When did DexCom's stock split? DexCom shares split on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly created shares were payable to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. What guidance has DexCom issued on next quarter's earnings? DexCom updated its FY 2023 earnings guidance on Friday, September, 15th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.50 billion-$3.55 billion, compared to the consensus revenue estimate of $3.54 billion. What is Kevin Sayer's approval rating as DexCom's CEO? 347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees. What other stocks do shareholders of DexCom own? Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP). What is DexCom's stock symbol? DexCom trades on the NASDAQ under the ticker symbol "DXCM." Who are DexCom's major shareholders? DexCom's stock is owned by many different institutional and retail investors. Top institutional shareholders include Bank Julius Baer & Co. Ltd Zurich (12.21%), Baillie Gifford & Co. (4.31%), Sands Capital Management LLC (3.38%), Capital Research Global Investors (2.35%), Geode Capital Management LLC (2.21%) and Jennison Associates LLC (1.88%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Bridgette P Heller, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Matthew Vincent Dolan, Michael Jon Brown, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal. View institutional ownership trends. How do I buy shares of DexCom? Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is DexCom's stock price today? One share of DXCM stock can currently be purchased for approximately $90.32. How much money does DexCom make? DexCom (NASDAQ:DXCM) has a market capitalization of $35.03 billion and generates $2.91 billion in revenue each year. The medical device company earns $341.20 million in net income (profit) each year or $0.86 on an earnings per share basis. How many employees does DexCom have? The company employs 7,600 workers across the globe. Does DexCom have any subsidiaries? The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.Read More How can I contact DexCom? DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.dexcom.com. The medical device company can be reached via phone at (858) 200-0200, via email at investorrelations@dexcom.com, or via fax at 858-200-0201. This page (NASDAQ:DXCM) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.